ArticleOncogene2017

A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.

E-J Choi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.